| Name | Title | Contact Details |
|---|
Caring People Alliance, founded in 1932, is a member of the Boys and Girls Clubs of America and the United Way. It is one of the Philadelphia region's largest human service agencies. Our primary focus is on children and youth and the matters that most
MTX Therapy Services is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WELL™ Health is upending the $3.5 trillion healthcare market by helping patients and administrators break free of antiquated communication practices. This 2021 Best in KLAS for Patient Outreach software provides medical organizations with a single command center that connects the many tools they use, transforming everyday interactions between patients and the doctor`s front office.
ovos natural health is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.